Global Non-invasive DNA Prenatal Testing Supply, Demand and Key Producers, 2023-2029

Global Non-invasive DNA Prenatal Testing Supply, Demand and Key Producers, 2023-2029

The global Non-invasive DNA Prenatal Testing market size is expected to reach $ 10360 million by 2029, rising at a market growth of 11.5% CAGR during the forecast period (2023-2029).

Non-invasive prenatal DNA testing is a new generation of prenatal testing technology that uses next-generation high-throughput sequencing to detect fetal chromosomal abnormalities.

This report studies the global Non-invasive DNA Prenatal Testing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Non-invasive DNA Prenatal Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Non-invasive DNA Prenatal Testing that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Non-invasive DNA Prenatal Testing total market, 2018-2029, (USD Million)

Global Non-invasive DNA Prenatal Testing total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Non-invasive DNA Prenatal Testing total market, key domestic companies and share, (USD Million)

Global Non-invasive DNA Prenatal Testing revenue by player and market share 2018-2023, (USD Million)

Global Non-invasive DNA Prenatal Testing total market by Type, CAGR, 2018-2029, (USD Million)

Global Non-invasive DNA Prenatal Testing total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Non-invasive DNA Prenatal Testing market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Illumina, Roche, Natera, Thermo Fisher Scientific, F. Hoffman-La Roche, Pacific Biosciences Of California, Perkinelmer, LifeCodexx and Agilent Technologies, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Non-invasive DNA Prenatal Testing market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Non-invasive DNA Prenatal Testing Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Non-invasive DNA Prenatal Testing Market, Segmentation by Type
Equipment
Consumables

Global Non-invasive DNA Prenatal Testing Market, Segmentation by Application
Hospital
Clinic
Other

Companies Profiled:
Illumina
Roche
Natera
Thermo Fisher Scientific
F. Hoffman-La Roche
Pacific Biosciences Of California
Perkinelmer
LifeCodexx
Agilent Technologies
Labcorp
Mutiplicon
Premaitha Health
Beijing BGI
Berry Genomics
Darui Biological

Key Questions Answered

1. How big is the global Non-invasive DNA Prenatal Testing market?

2. What is the demand of the global Non-invasive DNA Prenatal Testing market?

3. What is the year over year growth of the global Non-invasive DNA Prenatal Testing market?

4. What is the total value of the global Non-invasive DNA Prenatal Testing market?

5. Who are the major players in the global Non-invasive DNA Prenatal Testing market?

6. What are the growth factors driving the market demand?